Skip to main content
Clinical Trials/NCT06376279
NCT06376279
Enrolling by Invitation
N/A

Genetisk Diagnostik Vid medfödda Metabola Sjukdomar

Region Stockholm0 sites1,000 target enrollmentApril 29, 2008

Overview

Phase
N/A
Intervention
Not specified
Conditions
Metabolic Disease
Sponsor
Region Stockholm
Enrollment
1000
Primary Endpoint
Genetic variant identification using NGS for diagnosis
Status
Enrolling by Invitation
Last Updated
2 years ago

Overview

Brief Summary

Inborn Errors of metabolism comprise a large number of rare conditions with a collective incidence of around 1/2000 newborns. Many disorders are treatable provided that a correct diagnosis can be established in time, and for many diseases novel therapies are being developed. Without treatment, many of the conditions result in early death or severe irreversible handicaps.

The Centre for Inherited Metabolic Diseases, CMMS at Karolinska university hospital, is an integrated expert center where clinical specialists work closely together with experts in laboratory medicine, combining clinical genetics, clinical chemistry, pediatrics, neurology, and endocrinology. The center serves the whole Swedish population with diagnostics and expert advice on IEM and has a broad arsenal of biochemical investigations designed to detect defects in intermediary metabolism.

Detailed Description

Approximately one in two thousand infants is born with a metabolic disorder that often leads to brain damage. By means of high-tech genetic mapping using whole genome sequencing (WGS), we have discovered the molecular foundations for several of these diseases. For investigation of mitochondrial diseases, mitochondria are isolated from muscle biopsies for analysis of ATP production using a range of substrate combinations, determination of activities of respiratory chain complexes, and analysis of nuclear and mitochondrial DNA. The center also performs the national neonatal screening program, currently comprising 26 treatable diseases. Dried blood spot samples (DBS) are stored in the phenylketonuria (PKU) biobank, currently (2024 january) holding around 4.9 million of Sweden's 10.6 million inhabitants. Many metabolic disorders, however, lack effective counter-measures.

Registry
clinicaltrials.gov
Start Date
April 29, 2008
End Date
December 31, 2030
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Medical inferral, suspicion metabolic disease incl epilepsy and their relatives

Exclusion Criteria

  • Disease other than metabolic

Outcomes

Primary Outcomes

Genetic variant identification using NGS for diagnosis

Time Frame: Through study completion, an average of 1 year.

Variant identification in patients investigated at our clinic, Centre for inherited metabolic diseases, is an ongoing clinical activity. In many cases, if no variant is identified with NGS (Next Genenation Sequencing) using WGS, additional methods are used such as transcriptomics, proteomics and different cellmodels. More than 400 patients are investigated yearly with NGS/WGS in our clinic.

Similar Trials